Welcome to this episode!  We Talked to Michaels Quirmbach CEO of CordenPharma and discussed their ambitious plans and recent strategic moves. Michael will share insights on their record-breaking €1 billion investment over the next three years to expand peptide manufacturing across Europe and the US, including a major greenfield site outside Basel, Switzerland. We’ll explore what motivated this huge push, why Basel was chosen, and what sets CordenPharma apart in the competitive GLP-1 space. Plus, we'll get a sneak peek into other platform expansions and updates on CordenPharma’s sustainability and ESG initiatives. Stay tuned!

In this episode, we chat with Matt Minardi from Sterling Pharma about what's really happening in the outsourcing world right now. He shares his thoughts on the current trends, what's driving change in the industry, and how customer needs are evolving when working with CDMOs. We also touch on some of the biggest shifts and what the future might hold for the market.

We're excited to feature Alicia Xaka, of Procos SpA, a company renowned for its customer-centric approach to custom synthesis and innovative solutions in the API industry. Join us as we explore how Procos is redefining flexibility and responsiveness to meet the evolving needs of emerging therapies.